Rare Biomarkers Specimen Collection and Stabilization Market Report 2026

The rare biomarkers specimen collection and stabilization market size has grown rapidly in recent years. It will grow from $35.29 billion in 2025 to $38.94 billion in 2026 at a compound annual growth rate (CAGR) of 10.3%. The growth in the historic period can be attributed to growth in molecular diagnostics research, expansion of oncology biomarker studies, availability of plasma-based testing methods, increasing clinical trial activity, rising use of biobanking practices.

The rare biomarkers specimen collection and stabilization market size is expected to see strong growth in the next few years. It will grow to $55.35 billion in 2030 at a compound annual growth rate (CAGR) of 9.2%. The growth in the forecast period can be attributed to increasing adoption of precision diagnostics, rising demand for early disease detection, expansion of genomic and transcriptomic testing, growing investments in biomarker-driven drug development, increasing integration of ai in biomarker analysis. Major trends in the forecast period include increasing adoption of liquid biopsy collection techniques, growing use of advanced stabilization reagents, rising demand for high-sensitivity biomarker preservation, expansion of non-invasive diagnostic applications, enhanced focus on sample integrity and traceability.

The growing prevalence of cancer is expected to drive the expansion of the rare biomarker specimen collection and stabilization market in the coming years. Cancer encompasses a wide range of diseases characterized by the uncontrolled growth and spread of abnormal cells. The rising incidence of cancer is fueled by factors such as environmental exposures, lifestyle risks including smoking and unhealthy diets, and genetic predisposition, all of which increase the demand for accurate diagnostic and monitoring solutions. Rare biomarker specimen collection and stabilization are essential for preserving blood- and tissue-based biomarkers used in early cancer detection, molecular characterization, and treatment selection in oncology. For instance, in February 2024, according to the World Health Organization, a Switzerland-based intergovernmental organization, more than 35 million new cancer cases are projected by 2050, representing a 77% increase compared with the estimated 20 million cases in 2022. Therefore, the increasing prevalence of cancer is driving the growth of the rare biomarker specimen collection and stabilization market.

Major companies operating in the rare biomarkers specimen collection and stabilization market are emphasizing the development of advanced solutions, such as automated plasma and cell sample preparation technologies, to maintain biomarker integrity and support high-throughput multiomics analysis. Automated pre-analytical platforms are technologies that standardize blood sample processing steps, including plasma separation, cell fixation, and slide preparation at the point of collection, ensuring consistent sample quality without manual intervention or specialized collection tubes. For instance, in April 2024, Tethis S.p.A., an Italy-based biotechnology company, announced the enrollment of the first two patients in a clinical study of its See.d platform. This platform automates standardized plasma and cell sample preparation for multiomic liquid biopsy, including the fixation of rare circulating tumor and immune cells on nanocoated SmartBioSurface slides. It is designed to preserve sample integrity and enable integrated analysis of cell-free DNA and circulating tumor cells from a single blood draw, supporting the complete workflow of rare biomarker specimen collection and stabilization.

In June 2025, Foresight Diagnostics, a US-based diagnostics company specializing in ultra-sensitive minimal residual disease detection, partnered with QIAGEN to develop and commercialize a kit-based version of Foresight’s CLARITY assay. Through this partnership, the companies aim to convert a highly sensitive minimal residual disease liquid biopsy test based on circulating tumor DNA into a regulated in vitro diagnostic and companion diagnostic kit for lymphoma and other hematological cancers. QIAGEN is a Germany-based manufacturer and supplier of products used in rare biomarker specimen collection and stabilization.

Major companies operating in the rare biomarkers specimen collection and stabilization market are F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., Abbott Laboratories, Merck KGaA, Becton Dickinson and Company, Eurofins Scientific SE, Agilent Technologies Inc., PerkinElmer Inc., Illumina Inc., Charles River Laboratories International Inc., Bio-Rad Laboratories Inc., Bruker Corporation, QIAGEN N.V., Miltenyi Biotec GmbH, Natera Inc., Promega Corporation, Myriad Genetics, Hamilton Company, OraSure Technologies Inc., Fluidigm Corporation, Streck Inc., SeraCare, Enzo Biochem Inc., Epigenomics AG, Veridex LLC.

North America was the largest region in the rare biomarkers specimen collection and stabilization market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the rare biomarkers specimen collection and stabilization market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the rare biomarkers specimen collection and stabilization market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the rare biomarkers specimen collection and stabilization market by increasing costs of imported collection kits, stabilization reagents, specialized consumables, and analytical accessories. Diagnostic laboratories and research institutes in North America and Europe are most affected due to reliance on imported high-precision consumables, while Asia-Pacific faces cost pressure on expanding testing infrastructure. These tariffs are increasing operational costs and slowing adoption in routine diagnostics. However, they are also encouraging local production of collection kits, regional reagent manufacturing, and development of cost-efficient stabilization technologies.

The rare biomarkers specimen collection and stabilization market research report is one of a series of new reports that provides rare biomarkers specimen collection and stabilization market statistics, including rare biomarkers specimen collection and stabilization industry global market size, regional shares, competitors with a rare biomarkers specimen collection and stabilization market share, detailed rare biomarkers specimen collection and stabilization market segments, market trends and opportunities, and any further data you may need to thrive in the rare biomarkers specimen collection and stabilization industry. This rare biomarkers specimen collection and stabilization market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Rare biomarkers specimen collection and stabilization refers to the procedures involved in collecting and preserving biological samples that contain rare or low-abundance molecules serving as indicators of specific biological processes, diseases, or conditions. These biomarkers may include particular proteins, nucleic acids, metabolites, or other molecular substances. The purpose of collecting and stabilizing rare biomarkers is to ensure accurate and reliable measurement and analysis of these molecules for diagnostic, prognostic, and therapeutic uses.

The primary types of rare biomarker specimen collection and stabilization include circulating cell-free DNA, circulating tumor cells, exosomes, and extracellular vesicles. Circulating cell-free DNA consists of DNA fragments freely present in the bloodstream that can originate from both healthy and diseased cells. These fragments carry genetic information and can be analyzed for multiple diagnostic applications, such as cancer detection or monitoring treatment response. This process utilizes different specimen types, including serum, plasma, and others, across applications such as non-invasive prenatal testing, oncology, transcriptomics, pharmacogenomics, transplant rejection monitoring, population screening, cardiovascular disease assessment, and others. These solutions are used by a range of end users, including hospitals, perinatal clinics, public health laboratories, private or commercial laboratories, physician laboratories, research institutes, and others.

The rare biomarkers specimen collection and stabilization market consists of revenues earned by entities by providing services such as sample collection, stabilization and preservation, customized collection protocols, bio banking and storage and data management and reporting. The market value includes the value of related goods sold by the service provider or included within the service offering. The rare biomarkers specimen collection and stabilization market also includes sales of biomarker collection kits, laboratory equipment, training and educational materials, quality control materials, and sample storage containers. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.